SPOTLIGHT -
Dr. Allison Betof Warner on Outcomes With Anti-PD1 Therapy in Melanoma
Cancer Network spoke with Allison Betof Warner, MD, PhD, of Memorial Sloan Kettering Cancer Center, about long-term outcomes and responses to retreatment in patients with melanoma receiving anti-PD1 therapy.
Combination Controversies: Checkpoint Inhibition Alone or in Combination for the Treatment of Melanoma?
In this review, we highlight prospective data on checkpoint inhibition alone and in combination, discuss data regarding the efficacy and toxicity of combination therapy, and identify clinical scenarios that may favor treatment with combination therapy.
